Isoniazid Prophylaxis With Concomitant Cotrimoxazole in HIV-infected Children
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00330304|
Recruitment Status : Unknown
Verified September 2010 by University of Cape Town.
Recruitment status was: Active, not recruiting
First Posted : May 26, 2006
Last Update Posted : September 8, 2010
|Condition or disease||Intervention/treatment||Phase|
|Tuberculosis||Drug: Isoniazid Drug: Cotrimoxazole Drug: isoniazid Other: placebo||Phase 3|
Tuberculosis (TB) and HIV are dual pandemics occurring in South Africa. Prevention of TB and the subsequent decline in immune function in HIV-infected children is an important strategy to reduce mortality. Isoniazid (INH) prophylaxis reduces TB incidence in HIV-infected adults, but the efficacy in HIV-infected children has not been studied. In 2003, the investigators therefore began a double blind placebo controlled trial to investigate the impact of INH prophylaxis on mortality, morbidity and TB incidence in HIV-infected children. Interim analysis found a striking reduction in mortality and TB with a decrease in mortality in excess of 50% and 60% respectively, in children on INH. Based on this, the placebo arm was terminated; the study continued as a trial of thrice versus daily INH and cotrimoxazole (CTX). Although the results indicate an important benefit in children on INH, it is unknown what the long term efficacy and safety of INH prophylaxis is, what the optimal regime is and whether this pertains to children on HAART (who formed a minority of the cohort but who are still at risk for TB).
Aim To investigate the efficacy, safety and tolerability of INH and CTX as prophylactic strategies for HIV-infected children in a high TB prevalence area.
- To compare the long term impact of two different INH preventive regimens (daily versus thrice weekly) on TB incidence, occurrence of INH resistance in patients with culture-confirmed TB, mortality, incidence of adverse reactions and adherence
- To compare the long term impact of two different CTX prophylactic regimens (daily versus thrice weekly) on mortality, frequency and duration of hospitalization, type of serious infections, nasopharyngeal carriage of bacteria and development of antimicrobial resistance, adherence and incidence of adverse reactions
- To investigate the efficacy, safety and tolerability of INH compared with placebo for prevention of TB in children receiving HAART
Methods A prospective randomized double blind placebo controlled study of INH versus placebo in newly recruited HIV-infected children who are stable on HAART. In addition, an extended follow-up study of children already randomised to thrice weekly or daily INH and CTX. Children will be followed for 2 years with regular clinical evaluation, adherence assessment and laboratory monitoring. Outcomes measured will be mortality, TB incidence, morbidity, adherence and tolerability.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||450 participants|
|Intervention Model:||Factorial Assignment|
|Official Title:||Long Term Study of 2 Isoniazid (INH) Prophylactic Regimens With Concomitant Cotrimoxazole (CTX) in HIV-infected Children - Impact on Morbidity, Mortality, Bacterial Resistance and Incidence of Tuberculosis|
|Study Start Date :||January 2003|
|Estimated Primary Completion Date :||July 2011|
|Estimated Study Completion Date :||July 2011|
Experimental: Isoniazid preventive therapy
HIV infected children living in a high TB prevalence area receive isonaizid prophylaxis daily, together with cotrimoxazole prohpylaxis either 3 times a week or daily.
isoniazid 10mg/kg orally, daily, for study periodDrug: Cotrimoxazole
Cotrimoxazole given 3 times a week or daily, orally, for study periodDrug: isoniazid
Isoniazid, 10mg/kg daily for study period
Placebo Comparator: Placebo
HIV infected children living in a high TB prevalence area receive placebo once daily
Cotrimoxazole given 3 times a week or daily, orally, for study periodOther: placebo
Placebo tablet identicle in appearance to intervention: isoniazid table
- TB incidence [ Time Frame: Jan 2003 to July 2011 ]
- Mortality [ Time Frame: Jan 2003 to July 2011 ]
- intercurrent infections [ Time Frame: Jan 2003 to July 2011 ]
- adherence [ Time Frame: Jan 2003 to July 2011 ]
- adverse events [ Time Frame: Jan 2003 to July 2011 ]
- antimicrobial resistance [ Time Frame: Jan 2003 to July 2011 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00330304
|Red Cross Childrens Hospital|
|Cape Town, Western Cape, South Africa, 7700|
|Cape Town, Western Cape, South Africa|
|Principal Investigator:||Heather J Zar, MD PHd||University of Cape Town|
|Principal Investigator:||Mark Cotton, Md PhD||University of Stellenbosch|